5-(1-naphthalenyl)-1,3,4-oxadiazol-2(3H)-one | 304654-38-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-(1-naphthalenyl)-1,3,4-oxadiazol-2(3H)-one
• 英文别名: 5-naphthalen-1-yl-3H-1,3,4-oxadiazol-2-one
• CAS: 304654-38-4
• 化学式: C₁₂H₈N₂O₂
• 分子量: 212.208
• InChiKey: IKWOQGMVLATZJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  吗啉 、 5-(1-naphthalenyl)-1,3,4-oxadiazol-2(3H)-one 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 70.0h， 以89%的产率得到4-(5-naphthalen-1-yl-1,3,4-oxadiazol-2-yl)morpholine
  参考文献：
  名称：

  Efficient Phosphonium-Mediated Synthesis of 2-Amino-1,3,4-oxadiazoles

  摘要：

  We present an efficient, room temperature procedure for the preparation of 2-amino-1,3,4-oxadiazoles, Oxadiazol-2-ones can be activated for S(N)Ar substitution using phosphonium reagents (e.g., BOP). This approach provides convenient access to N,N-disubstituted 2-amino-1,3,4-oxadiazoles, which are difficult to prepare using existing synthetic strategies.

  DOI：

  10.1021/ol8004084
• 作为产物：
  描述：

  三光气 、 1-萘甲酰肼 以 四氢呋喃 为溶剂， 以77%的产率得到5-(1-naphthalenyl)-1,3,4-oxadiazol-2(3H)-one
  参考文献：
  名称：

  Efficient Phosphonium-Mediated Synthesis of 2-Amino-1,3,4-oxadiazoles

  摘要：

  We present an efficient, room temperature procedure for the preparation of 2-amino-1,3,4-oxadiazoles, Oxadiazol-2-ones can be activated for S(N)Ar substitution using phosphonium reagents (e.g., BOP). This approach provides convenient access to N,N-disubstituted 2-amino-1,3,4-oxadiazoles, which are difficult to prepare using existing synthetic strategies.

  DOI：

  10.1021/ol8004084

文献信息

• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
• [EN] BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS<br/>[FR] DÉRIVÉS BENZODIAZÉPINE UTILISÉS COMME INHIBITEURS DU VIRUS RESPIRATOIRE SYNCYTIAL (RSV)
  申请人：ENANTA PHARM INC

  公开号：WO2017015449A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药：这些化合物抑制呼吸道合胞病毒（RSV）。本发明还涉及包含上述化合物的药物组合物，用于治疗患有RSV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的RSV感染的方法。
• The use of a Mitsunobu reagent for the formation of heterocycles: a simple method for the preparation of 3-alkyl-5-aryl-1,3,4-oxadiazol-2(3H)-ones from carboxylic acids
  作者：Osamu Sugimoto、Tomoyo Arakaki、Hiroka Kamio、Ken-ichi Tanji

  DOI：10.1039/c4cc01971g

  日期：——

  The reaction of carboxylic acids with Mitsunobu reagents, prepared by the reaction of triphenylphosphine with dialkyl azodicarboxylates, followed by heating at 180-190 degrees C under solvent-free conditions, afforded 3-alkyl-5-aryl-1,3,4-oxadiazol-2(3H)-ones. This facile and convenient method readily provides the 1,3,4-oxadiazolone ring systems in good yields using a one-pot protocol starting from

  通过三苯膦与偶氮二羧酸二烷基酯的反应制备羧酸，与Mitsunobu试剂反应，然后在无溶剂的条件下于180-190℃加热，得到3-烷基-5-芳基-1,3,4-恶二唑-2（3H）-一个 这种简便易行的方法可以使用一锅法从相应的羧酸开始轻松地以高收率提供1,3,4-恶二唑酮环系统。还证明了催化碱的存在有助于形成1,3,4-恶二唑-2（3H）-one的最终闭环。
• Benzodiazepine derivatives as RSV inhibitors
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10570153B2

  公开（公告）日：2020-02-25

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： 其可抑制呼吸道合胞病毒（RSV）。本发明进一步涉及包含上述化合物的药物组合物，用于给受 RSV 感染的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 RSV 感染的方法。
• Combination pharmaceutical agents as RSV inhibitors
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10881666B2

  公开（公告）日：2021-01-05

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及向受试者联合或系列施用治疗呼吸道合胞病毒（RSV）感染的药剂，其中治疗包括施用一种有效抑制 RSV 功能的化合物和另外一种或多种具有抗 RSV 活性的化合物组合。